Bionexus Gene Lab Corp (BGLC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Sales | 23 | 484 | 2,544 | 2,260 | 2,137 |
| Cost of Goods | 24 | 488 | 2,166 | 1,892 | 1,794 |
| Gross Profit | -1 | -4 | 378 | 368 | 344 |
| Operating Expenses | 563 | 1,517 | 1,246 | 1,872 | 1,756 |
| Operating Income | -541 | -1,033 | -703 | -611 | -618 |
| Interest Expense | 17 | 10 | 21 | 30 | 24 |
| Other Income | 14 | 7 | 14 | 25 | 19 |
| Pre-tax Income | -544 | -1,036 | -709 | -616 | -623 |
| Net Income Continuous | -544 | -1,036 | -709 | -616 | -623 |
| Net Income | $-544 | $-1,036 | $-709 | $-616 | $-623 |
| EPS Basic Total Ops | -0.23 | -0.52 | -0.40 | -0.34 | -0.35 |
| EPS Basic Continuous Ops | -0.22 | -0.52 | -0.39 | -0.34 | -0.35 |
| EPS Diluted Total Ops | -0.23 | -0.52 | -0.40 | -0.34 | -0.35 |
| EPS Diluted Continuous Ops | -0.22 | -0.52 | -0.39 | -0.34 | -0.35 |
| EPS Diluted Before Non-Recurring Items | -0.23 | -0.52 | -0.39 | -0.34 | -0.03 |
| EBITDA(a) | $-479 | $-980 | $-638 | $-540 | $-555 |